Drugs during pregnancy and lactation: treatment options and risk assessment
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Amsterdam [u.a.]
Elsevier, Acad. Press
2007
|
| Ausgabe: | 2. ed. |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XXV, 875 S. Beil. |
| ISBN: | 9780444520722 0444520724 |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV022399517 | ||
| 003 | DE-604 | ||
| 005 | 20070711 | ||
| 007 | t | ||
| 008 | 070424s2007 ne |||| 00||| eng d | ||
| 020 | |a 9780444520722 |9 978-0-444-52072-2 | ||
| 020 | |a 0444520724 |9 0-444-52072-4 | ||
| 035 | |a (OCoLC)170029613 | ||
| 035 | |a (DE-599)BVBBV022399517 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 044 | |a ne |c NL | ||
| 049 | |a DE-355 |a DE-Er8 |a DE-19 | ||
| 050 | 0 | |a RG627.6.D79 | |
| 082 | 0 | |a 618.32 |2 22 | |
| 084 | |a XI 2368 |0 (DE-625)152984:12975 |2 rvk | ||
| 245 | 1 | 0 | |a Drugs during pregnancy and lactation |b treatment options and risk assessment |c ed. by Christof Schaefer ... |
| 250 | |a 2. ed. | ||
| 264 | 1 | |a Amsterdam [u.a.] |b Elsevier, Acad. Press |c 2007 | |
| 300 | |a XXV, 875 S. |e Beil. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a Drug Therapy |x adverse effects | |
| 650 | 4 | |a Fetus |x Effect of drugs on |v Handbooks, manuals, etc | |
| 650 | 4 | |a Fetus |x drug effects | |
| 650 | 4 | |a Infant, Newborn | |
| 650 | 4 | |a Lactation |x drug effects | |
| 650 | 4 | |a Newborn infants |x Effect of drugs on |v Handbooks, manuals, etc | |
| 650 | 4 | |a Obstetrical pharmacology |v Handbooks, manuals, etc | |
| 650 | 4 | |a Pregnancy | |
| 650 | 4 | |a Pregnancy |x drug effects | |
| 650 | 4 | |a Pregnant women |x Drug use | |
| 650 | 4 | |a Pregnant women |x Medical care | |
| 650 | 0 | 7 | |a Stillperiode |0 (DE-588)4183337-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittel |0 (DE-588)4003115-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Schwangerschaft |0 (DE-588)4053724-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Stillen |0 (DE-588)4057578-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelnebenwirkung |0 (DE-588)4003134-2 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Stillperiode |0 (DE-588)4183337-5 |D s |
| 689 | 0 | 1 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Schwangerschaft |0 (DE-588)4053724-9 |D s |
| 689 | 1 | 1 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Schwangerschaft |0 (DE-588)4053724-9 |D s |
| 689 | 2 | 1 | |a Stillen |0 (DE-588)4057578-0 |D s |
| 689 | 2 | 2 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 2 | 3 | |a Arzneimittelnebenwirkung |0 (DE-588)4003134-2 |D s |
| 689 | 2 | |8 1\p |5 DE-604 | |
| 700 | 1 | |a Schaefer, Christof |d 1951- |e Sonstige |0 (DE-588)132428474 |4 oth | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015608213&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-015608213 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
Datensatz im Suchindex
| _version_ | 1804136460691963904 |
|---|---|
| adam_text | Contents
List of contributors xxjj
Preface
Notice
General commentary on drug therapy and drug risks in
pregnancy
Richard K. Miller, Paul W. Peters, and
1.1
Introduction
2
1.2
Development and health
3
1.3
Reproductive stages
3
1.4
Reproductive and developmental toxicology
6
1.5
Basic principles of drug-induced reproductive and developmental
toxicology
9
1.6
Effects and manifestations
10
1.7
Pharmacokinetics in pregnancy
12
1.8
Passage of drugs to the unborn and fetal kinetics
13
1.9
Causes of developmental disorders
14
1.10
Embryo/fetotoxic risk assessment
15
1.11
Classification of drugs used in pregnancy
19
1.12
Paternal use of medicinal products
20
1.13
Communicating the risk of drug use in pregnancy
21
1.14
Risk communication prior to pharmacotherapeutic choice
22
1.15
Risk communication regarding the safety (or otherwise) of drugs
already used in pregnancy
23
1.16
Teratology information centers
24
Specific drug therapies during pregnancy
2.1
Minke
28
29
32
32
33
33
34
2.1.1
Paracetamol (acetaminophen)
2.1.2
Aspirin (aceJylsaiicylic acid)
2.1.3
Pyrazolone derivatives
2.1.4
Combination analgesic preparations
2.1.5
Opioid analgesics in general
2.1.6
Morphine
2.1.7
Codeine
v¡
2.1.8
2.1.9
2.1.10
2.1.11
2.1.12
2.1.13
2.1.14
2.1.15
2.1.16
2.1.17
2.1.18
2.1.19
2.2
Margreet
2.2.1
2.2.2
2.2.3
2.2.4
2.3
Hanneke
2.3.1
2.3.2
2.3.3
2.3.4
2.3.5
2.3.6
2.3.7
2.3.8
2.3.9
2.3.10
2.3.11
2.3.12
2.4
iee H. Goldstein and
2.4.1
2.4.2
2.4.3
2.4.4
2.4.5
2.4.6
Contents
2.4.7 Antihistamines (fy-blockers) 83
2.4.8 Dopamine
2.4.9
2.4.10 Thiamine
2.4.11
2.4.12
2.4.13
2.5
Margreet
2.5.1
2.5.2
2.5.3
2.5.4
2.5.5
2.5.6
2.5.7
2.5.8
2.5.9
2.5.10
2.5.11
2.5.12
2.5.13
2.5.14
2.5.15
2.5.16
2.5.17
2.5.18
2.5.19
2.5.20
2.5.21
2.5.22
2.5.23
2.5.24
2.5.25
2.5.26
2.6
Hanneke
2.6.1
2.6.2
2.6.3
2.6.4
viii Contents
2.6.5
128
2.6.6
128
2.6.7
129
2.6.8
131
2.6.9
132
2.6.10
133
2.6.11
134
2.6.12
135
2.6.13
136
2.6.14
136
2.6.15
137
2.6.16
137
2.6.17
138
2.6.18
138
2.6.19
139
2.6.20
140
2.6.21
141
2.6.22
142
2.6.23
142
2.6.24
143
2.6.25
144
2.6.26
144
2.6.27
145
2.6.28
146
2.6.29
147
2.6.30
148
2.6.31
148
2.6.32
149
2.6.33
150
2.6.34
151
2.6.35
152
2.6.36
153
2.6.37
153
2.6.38
154
2.6.39
154
2.6.40
154
2.6.41
155
2.6.42
155
2.6.43
156
2.6.44
156
2.6.45
158
2.6.46
158
2.6.47
159
2.6.48 HIV
159
Contents ix
2.7
2.8
2.6.49 Mebendazole and flubendazole
162
2.6.50 Pyrviniumembonate
163
2.6.51 Albendazole and thiabendazole
164
2.6.52 Nidosamide
164
2.6.53 Praziquantel
165
2.6.54 Pyrantel
165
2.6.55 Ivermectin and diethylcarbamazine
166
2.6.56 Hyperthermia
166
2.6.57
168
Vaccines and immunoglobulins
178
Paul Peters
2.7.1
179
2.7.2
180
2.7.3
180
2.7,4
180
2.7.5
181
2.7.6
182
2.7.7
182
2.7.8
183
2.7.9
184
2.7.10
184
2.7.11
184
2.7.12
185
2.7.13
186
2.7.14
187
2.7.15
187
2.7.16
188
2.7.17
189
2.7.18
189
Heart and circulatory system drugs and diuretics
193
Corinna
2.8.1
194
2.8.2
195
2.8.3
196
2.8.4
198
2.8.5
200
2.8.6
203
2.8.7
205
2.8.8
207
2.8.9
208
2.8.10
208
2.8.11
209
Contents
2.8.12
Reserpine
209
2.8.13
Other antihypertensives
210
2.8.14
Pulmonary hypertension and its medication
211
2.8.15
Hypotension and antihypotensives
214
2.8.16
Dihydroergotamine
215
2.8.17
Adrenergic substances
216
2.8.18
Cardiac glycosides
216
2.8.19
Antiarrhythmic therapy of the pregnant woman and
of the fetus
217
2.8.20
Nitrates and other so-called vasodilators
222
2.8.21
Cardiovascular drugs
223
2.8.22
Diuretics
224
2.8.23
Thiazide diuretics
224
2.8.24
Furosemide and other high-ceiling diuretics
225
2.8.25
Aldosterone antagonists
226
2.8.26
Amiloride and triamterene
227
2.8.27
Mannitol
227
2.9
237
Minke
2.9.1
Pregnancy and coagulation
237
2.9.2
Heparins
239
2.9.3
Protamines
240
2.9.4
Low-dose aspirin (LDA)
241
2.9.5
Other non-coumarin antithrombotic drugs
241
2.9.6
Vitamin
242
2.9.7
Vitamin
246
2.9.8
Fibrinolysis
247
2.9.9
Streptoicinase
247
2.9.10
Other fibrinolytics
248
2.9.11
Inhibitors of fibrinolysis
249
2.9.12
Volume expanders
249
2.10
254
Elisabeth Robert-Gnansia and
2.10.1
Epilepsy and antiepileptic drugs in pregnancy
255
2.10.2
Benzodiazepines
257
2.10.3
Carbamazepine
260
2.10.4
Ethosuximide and other succimides
261
2.10.5
Oxazolidine anticonvuisants
262
2.10.6
Phénobarbital
263
2.10.7
Phenytoin
266
2.10.8
Sultiam
268
2.10.9
Valproic acid
269
Contents xi
2.11
2.12
2.10.10 Felbamate
273
2.10.11 Gabapentin
273
2.10.12 Lamotrigine
274
2.10.13 Levetiracetam
276
2.10.14 Oxcarbazepine
277
2.10.15 Pregabalin
278
2.10.16 Tiagabine
278
2.10.17 Topiramate
279
2.10.18 Vigabatrin
279
2.10.19 Zonisamid
280
Psychotropic drugs
288
Hanneke Garbis and Patricia R. McEihatton
2.11.1 Tricyclic and tetracyclic antidepressants
289
2.11.2
291
2.11,3 Monoaminoxidase
296
2.11.4
297
2.11.5
atypical antipsychotics?
299
2.11.6
300
2.11.7
301
2.11.8
302
2.11.9
304
2.11.10
305
2.11.11
306
2.11.12
307
2.11.13
309
2.11.14
309
2.11.15
310
2.11.16
310
2.11.17
311
2.11.18
312
Immunomodulators
321
Corinna Weber-Schöndorfer
2.12.1 Immunomodulators in
321
2.12.2
322
2.12.3
323
2.12.4
324
2.12.5
immunomodulatory therapy
326
2.12.6
327
2.12.7 Thalidomide
329
2.12.8
330
xii Contents
2.13
Corinna Weber-Schöndorferand Christof Schaefer
2.13.1
2.13.2
2.13.3
2.13.4
2.13.5
2.13.6
2.13.7
2.13.8
2.13.9
2.13.10
2.13.11
2.13.12
2.13.13
2.13.14 Platin
2.13.15
2.13.16
2.13.17
2.13.18
2.13.19
2.14
and local contraceptives
Herman van Geijn
2.14.1
2.14.2
2.14.3
2.14.4
2.14.5 ß2-sympathomimetics 373
2.14.6
2.14.7
2.14.8
2.14.9
2.14.10
2.14.11
2.14.12
2.14.13
2.15
Elvira Rodriguez-Pinilla and
2.15.1
2.15.2
Contents xiii
2.15.3
Prolactin antagonists
386
2.15.4
Posterior pituitary hormones
387
2.15.5
Thyroid function and iodine supply during pregnancy
388
2.15.6
Hypothyroidism, triiodothyronine (T3), and thyroxine (T4)
389
2.15.7
Hyperthyroidism and thyrostatics
390
2.15.8
Glucocorticoids
392
2.15.9
Diabetes mellitus and pregnancy
397
2.15.10
Insulin
399
2.15.11
Oral antidiabetics
401
2.15.12
Estrogens
404
2.15.13
Progesti
405
2.15.14
Diethylstilbestrol
408
2.15.15
Androgens and anabolics
408
2.15.16
Antiestrogens, antiandrogens, and danazol
409
2.15.17
Mifepristone (RU486)
410
2.15.18
Clomiphene
411
2.16
I and local anesthetics and muscle
423
Asher
2.16.1
Halogenated inhalation agents for general anesthesia
424
2.16.2
Ether (diethyl ether)
426
2.16.3
Nitrous oxide
427
2.16.4
Injectable
427
2.16.5
Local anesthetics
431
2.16.6
Epidural and spinal analgesia/anesthesia in pregnancy
432
2.16.7
Muscle
433
2.16.8
Occupational exposure to inhalation anesthetics
434
2.17
441
Paul Peters and
2.17.1
Typical skin changes during pregnancy
441
2.17.2
Anti-infective agents
442
2.17.3
Antiseptics and disinfectants
444
2.17.4
Astringents
447
2.17.5
Polidocanol
448
2.17.6
Camphor and menthol
448
2.17.7
Coal tar and slate oil preparations
448
2.17.8
Local immunomoduiators and neurodermatitis therapy
449
2.17.9
Keratolytics
449
2.17.10
Retinoids for acne and psoriasis therapy
452
2.17.11
Photochemotherapy and
456
2.17.12
Sex hormones and cyproterone acetate
456
2.17.13
S-Fluorouracil
457
xiv Contents
2.17.14 Lithium 457
2.17.15
2.17.16 Diethyltoluamide
2.17.17
2.17.18
2.17.19
2.17.20
2.17.21
2.17.22
2.18
Paul Peters and
2.18.1
468
2.18.2
470
2.18.3
470
2.18.4
471
2.18.5
471
2.18.6
471
2.18.7
472
2.18.8
474
2.18.9
475
2.18.10
476
2.18.11
476
2.18.12
477
2.18.13
477
2.18.14
478
2.18.15
479
2.18.16
479
2.18.17
480
2.18.18
481
2.18.19
481
2.19
Henry M. Hess and Richard K. Miller
2.19.1
2.19.2
2.19.3
pregnancy
2.19.4
2.19.5
2.19.6
2.19.7
2.19.8
Contents xv
2.20
2.21
2.22
Diagnostic agents
502
Elisabeth Robert-Gnansia
2.20.1
502
2.20.2
505
2.20.3
506
2.20.4
507
2.20.5
507
2.20.6 Ultrasonographic
508
2.20.7
508
2.20.8
509
2.20.9
510
2.20.10
510
Recreational drugs
514
Paul Peters and
2.21.1
514
2.21.2
520
2.21.3
521
2.21.4
525
2.21.5
525
2.21.6
527
2.21.7
530
2.21.8
533
Poisonings and toxins
543
Christof
2.22.1
543
2.22.2
544
2.22.3
545
2.22.4
549
2.22.5
554
2.22.6
555
2.22.7
556
2.22.8
556
2.23
Richard K. Miller, Paul Peters, and Patricia R. McElhatton
2.23.1
2.23.2
2.23.3
2.23.4
2.23.5
xvi Contents
2.23.6
576
2.23.7
dibenzo-dioxins
581
2.23.8
583
2.23.9
590
2.23.10
592
2.23.11
594
2.23.12
596
2.23.13
596
2.23.14
598
General commentary on drug therapy and drug risk
during lactation
Ruth Lawrence and
3.1
medication
3.2
3.3
3.4
3.5
3.6
3.7
3.8
Christof
4.1
Christof
4.1.1
4.1.2
4.1.3
4.1.4
4.1.5
4.1.6
4.1.7
4.1.8
4.1.9
4.1.10
4.1.11
4.1.12
Contents xvii
4.2
4.3
4.4
Antiallergics, antiasthmatics and antitussives
639
Christof Schaefer
4.2.1
Antihistamines
639
4.2.2
ß2-sympathomimetics
641
4.2.3
Other sympathomimetics
642
4.2.4
Anticholinergics for asthma treatment
642
4.2.5
Theophylline
642
4.2.6
Cromoglycic acid and nedocromil
643
4.2.7
Corticoids
643
4.2.8
Leukotrien-receptor antagonists
644
4.2.9
Acetylcysteine and other mucolytics
644
4.2.10
Antitussives
644
Gastrointestinal drugs
648
Christof Schaefer
4.3.1
Antacids
648
4.3.2
H2-receptor
649
4.3.3
Peristaltic stimulators
650
4.3.4
Cholinergics
651
4.3.5
Anticholinergic spasmolytics
652
4.3.6
Laxatives
652
4.3.7
Agents used for chronic inflammatory bowel diseases
653
4.3.8
Antidiarrheals for acute diarrhea
654
4.3.9
Carminatives
654
4.3.10
Lipid
655
4.3.11
Chenodeoxycholic acid and ursodeoxycholic acid
655
4.3.12
Appetite suppressants
656
4.3.13
Antiemetics
656
Anti-infectives
659
Christof Schaefer
4.4.1
Antibiotics in general
660
4.4.2
Penicillins, cephalosporins, and other
660
4.4.3
Erythromycin and other macrolides
661
4.4.4
Tetracyclines
662
4.4.5
Dapsone, nitrofurantoin, and other drugs for urinary
tract infections
662
4.4.6
Quinolones
663
4.4.7
Other antibiotics and urinary tract antiseptics
664
4.4.8
Nitroimidazole antibiotics
665
4.4.9
Aminoglycoside antibiotics
665
4.4.10
Tuberculostatics
666
4.4.11
Malarial drugs
667
4.4.12
Local antimvcotics
668
xviii Contents
4.4.13
4.4.14
4.4.15
4.5
Ruth Lawrence and Christof Schaefer
4.5.1
4.5.2
4.5.3
4.5.4
4.5.5
4.5.6
4.5.7
4.5.8
4.5.9
4.5.10
4.5.11
680
682
682
683
684
684
685
686
686
687
690
4.6.12
4.7
Christof
695
696
696
697
699
700
700
4.6
Christof
4.6.1
ß-reeeptor blockers
4.6.2
Hydralazine
4.6.3
α
4.6.4
Calcium antagonists
4.6.5
ACE inhibitors
4.6.6
Angiotensin-ll receptor-antagonists
4.6.7
Other antihypertensives
4.6.8
Dihydroergotamine and other antihypotensives
4.6.9
Digitalis
4.6.10
Antiarrhythmics
4.6.11
Diuretics
4.7.1
Hepann
4.7.2
Vitamin
indanediones)
4.7.3
Other anticoagulants
4.7.4
Fibrinolytics
4.8
Christof
4.8.1
Carbamazepine
4.8.2
Clobazam and clonazepam
Contents xix
4.8.3
4.8.4
barbexaclone
4.8.5
4.8.6
4.8.7
4.8.8
4.8.9
4.8.10
4.8.11
4.8.12
4.8.13
4.8.14
4.8.15
4.9
708
709
714
718
720
724
724
727
727
730
731
732
732
4.10
Ruth Lawrence and
4.10.1
4.10.2
4.11
Christof
4.11.1
4.11.2
4.11.3
4.11.4
4.11.5
4.11.6
Psychotropic drugs
Christof
4.9.1
Antidepressants in general
4.9.2
Tri-
4.9.3
Selective serotonin reuptake inhibitors
4.9.4
Other antidepressants
4.9.5
Phenothiazine and thioxanthene neuroleptics
4.9.6
Butyrophenones
4.9.7
Atypical neuroleptics
4.9.8
Antimanic drugs
4.9.9
Benzodiazepines
4.9.10
Other anxiolytics
4.9.11
Other hypnotics
4.9.12
Psychoanaleptics
4.9.13
Parkinson drugs
XX
Contents
4.11.7 Corticosteroids
4.11.8
4.11.9 Insulin and oral antidiabetics
4.11.10 Estrogens,
4.11.11 Androgens
4.11.12
4.11.13 Prostaglandins
4.12 Dermatological
Ruth Lawrence and
4.12.1
products, sunscreens
4.12.2
4.12.3
4.12.4
4.12.5
4.12.6
4.12.7
4.13
Ruth Lawrence and
4.13.1
4.13.2
4.13.3
4.13.4
4.13.5
4.13.6
4.13.7
4.14
Ruth Lawrence and
4.14.1
4.14.2
4.14.3
4.14.4
4.14.5
4.14.6
4.15
Ruth Lawrence and
4.15.1
4.15.2
Simple infections
Mastitis
752
753
754
755
757
757
758
762
762
763
765
766
766
767
768
771
771
773
775
775
776
777
777
779
779
780
781
782
783
784
786
786
787
Contents xxi
787
788
788
790
790
791
791
793
794
794
797
797
798
800
800
801
803
804
4.17 Plant
Ruth Lawrence and Christof Schaefer
4.18
Christof Schaefer
4.18.1 Persistent organochlorine
polychlorinated biphenyls and dioxins) 811
4.18.2
4.18.3
4.18.4
4.18.5
4.18.6
4.18.7
Appendix A: Teratology information services and centers
Appendix B: Addresses for breastfeeding support
Subject index
4.15.3
Hepatitis A
4.15.4
Hepatitis
4.15.5
Hepatitis
4,15.6
Hepatitis
4.15.7
Herpes simplex
4.15.8
Herpes zoster (shingles), chickenpox
4.15.9
HIV
4.15.10
Human cytomegalovirus
4.15.11
Tuberculosis
4.15.12
Other infectious diseases
4.16
Ruth Lawrence and
4.16.1
Alcohol
4.16.2
Caffeine
4.16.3
Cannabis
4.16.4
Cocaine
4.16.5
Nicotine
4.16.6
Opiates, including methadone
4.16.7
Other drugs
|
| adam_txt |
Contents
List of contributors xxjj
Preface
Notice
General commentary on drug therapy and drug risks in
pregnancy
Richard K. Miller, Paul W. Peters, and
1.1
Introduction
2
1.2
Development and health
3
1.3
Reproductive stages
3
1.4
Reproductive and developmental toxicology
6
1.5
Basic principles of drug-induced reproductive and developmental
toxicology
9
1.6
Effects and manifestations
10
1.7
Pharmacokinetics in pregnancy
12
1.8
Passage of drugs to the unborn and fetal kinetics
13
1.9
Causes of developmental disorders
14
1.10
Embryo/fetotoxic risk assessment
15
1.11
Classification of drugs used in pregnancy
19
1.12
Paternal use of medicinal products
20
1.13
Communicating the risk of drug use in pregnancy
21
1.14
Risk communication prior to pharmacotherapeutic choice
22
1.15
Risk communication regarding the safety (or otherwise) of drugs
already used in pregnancy
23
1.16
Teratology information centers
24
Specific drug therapies during pregnancy
2.1
Minke
28
29
32
32
33
33
34
2.1.1
Paracetamol (acetaminophen)
2.1.2
Aspirin (aceJylsaiicylic acid)
2.1.3
Pyrazolone derivatives
2.1.4
Combination analgesic preparations
2.1.5
Opioid analgesics in general
2.1.6
Morphine
2.1.7
Codeine
v¡
2.1.8
2.1.9
2.1.10
2.1.11
2.1.12
2.1.13
2.1.14
2.1.15
2.1.16
2.1.17
2.1.18
2.1.19
2.2
Margreet
2.2.1
2.2.2
2.2.3
2.2.4
2.3
Hanneke
2.3.1
2.3.2
2.3.3
2.3.4
2.3.5
2.3.6
2.3.7
2.3.8
2.3.9
2.3.10
2.3.11
2.3.12
2.4
iee H. Goldstein and
2.4.1
2.4.2
2.4.3
2.4.4
2.4.5
2.4.6
Contents
2.4.7 Antihistamines (fy-blockers) 83
2.4.8 Dopamine
2.4.9
2.4.10 Thiamine
2.4.11
2.4.12
2.4.13
2.5
Margreet
2.5.1
2.5.2
2.5.3
2.5.4
2.5.5
2.5.6
2.5.7
2.5.8
2.5.9
2.5.10
2.5.11
2.5.12
2.5.13
2.5.14
2.5.15
2.5.16
2.5.17
2.5.18
2.5.19
2.5.20
2.5.21
2.5.22
2.5.23
2.5.24
2.5.25
2.5.26
2.6
Hanneke
2.6.1
2.6.2
2.6.3
2.6.4
viii Contents
2.6.5
128
2.6.6
128
2.6.7
129
2.6.8
131
2.6.9
132
2.6.10
133
2.6.11
134
2.6.12
135
2.6.13
136
2.6.14
136
2.6.15
137
2.6.16
137
2.6.17
138
2.6.18
138
2.6.19
139
2.6.20
140
2.6.21
141
2.6.22
142
2.6.23
142
2.6.24
143
2.6.25
144
2.6.26
144
2.6.27
145
2.6.28
146
2.6.29
147
2.6.30
148
2.6.31
148
2.6.32
149
2.6.33
150
2.6.34
151
2.6.35
152
2.6.36
153
2.6.37
153
2.6.38
154
2.6.39
154
2.6.40
154
2.6.41
155
2.6.42
155
2.6.43
156
2.6.44
156
2.6.45
158
2.6.46
158
2.6.47
159
2.6.48 HIV
159
Contents ix
2.7
2.8
2.6.49 Mebendazole and flubendazole
162
2.6.50 Pyrviniumembonate
163
2.6.51 Albendazole and thiabendazole
164
2.6.52 Nidosamide
164
2.6.53 Praziquantel
165
2.6.54 Pyrantel
165
2.6.55 Ivermectin and diethylcarbamazine
166
2.6.56 Hyperthermia
166
2.6.57
168
Vaccines and immunoglobulins
178
Paul Peters
2.7.1
179
2.7.2
180
2.7.3
180
2.7,4
180
2.7.5
181
2.7.6
182
2.7.7
182
2.7.8
183
2.7.9
184
2.7.10
184
2.7.11
184
2.7.12
185
2.7.13
186
2.7.14
187
2.7.15
187
2.7.16
188
2.7.17
189
2.7.18
189
Heart and circulatory system drugs and diuretics
193
Corinna
2.8.1
194
2.8.2
195
2.8.3
196
2.8.4
198
2.8.5
200
2.8.6
203
2.8.7
205
2.8.8
207
2.8.9
208
2.8.10
208
2.8.11
209
Contents
2.8.12
Reserpine
209
2.8.13
Other antihypertensives
210
2.8.14
Pulmonary hypertension and its medication
211
2.8.15
Hypotension and antihypotensives
214
2.8.16
Dihydroergotamine
215
2.8.17
Adrenergic substances
216
2.8.18
Cardiac glycosides
216
2.8.19
Antiarrhythmic therapy of the pregnant woman and
of the fetus
217
2.8.20
Nitrates and other so-called vasodilators
222
2.8.21
Cardiovascular drugs
223
2.8.22
Diuretics
224
2.8.23
Thiazide diuretics
224
2.8.24
Furosemide and other high-ceiling diuretics
225
2.8.25
Aldosterone antagonists
226
2.8.26
Amiloride and triamterene
227
2.8.27
Mannitol
227
2.9
237
Minke
2.9.1
Pregnancy and coagulation
237
2.9.2
Heparins
239
2.9.3
Protamines
240
2.9.4
Low-dose aspirin (LDA)
241
2.9.5
Other non-coumarin antithrombotic drugs
241
2.9.6
Vitamin
242
2.9.7
Vitamin
246
2.9.8
Fibrinolysis
247
2.9.9
Streptoicinase
247
2.9.10
Other fibrinolytics
248
2.9.11
Inhibitors of fibrinolysis
249
2.9.12
Volume expanders
249
2.10
254
Elisabeth Robert-Gnansia and
2.10.1
Epilepsy and antiepileptic drugs in pregnancy
255
2.10.2
Benzodiazepines
257
2.10.3
Carbamazepine
260
2.10.4
Ethosuximide and other succimides
261
2.10.5
Oxazolidine anticonvuisants
262
2.10.6
Phénobarbital
263
2.10.7
Phenytoin
266
2.10.8
Sultiam
268
2.10.9
Valproic acid
269
Contents xi
2.11
2.12
2.10.10 Felbamate
273
2.10.11 Gabapentin
273
2.10.12 Lamotrigine
274
2.10.13 Levetiracetam
276
2.10.14 Oxcarbazepine
277
2.10.15 Pregabalin
278
2.10.16 Tiagabine
278
2.10.17 Topiramate
279
2.10.18 Vigabatrin
279
2.10.19 Zonisamid
280
Psychotropic drugs
288
Hanneke Garbis and Patricia R. McEihatton
2.11.1 Tricyclic and tetracyclic antidepressants
289
2.11.2
291
2.11,3 Monoaminoxidase
296
2.11.4
297
2.11.5
atypical antipsychotics?
299
2.11.6
300
2.11.7
301
2.11.8
302
2.11.9
304
2.11.10
305
2.11.11
306
2.11.12
307
2.11.13
309
2.11.14
309
2.11.15
310
2.11.16
310
2.11.17
311
2.11.18
312
Immunomodulators
321
Corinna Weber-Schöndorfer
2.12.1 Immunomodulators in
321
2.12.2
322
2.12.3
323
2.12.4
324
2.12.5
immunomodulatory therapy
326
2.12.6
327
2.12.7 Thalidomide
329
2.12.8
330
xii Contents
2.13
Corinna Weber-Schöndorferand Christof Schaefer
2.13.1
2.13.2
2.13.3
2.13.4
2.13.5
2.13.6
2.13.7
2.13.8
2.13.9
2.13.10
2.13.11
2.13.12
2.13.13
2.13.14 Platin
2.13.15
2.13.16
2.13.17
2.13.18
2.13.19
2.14
and local contraceptives
Herman van Geijn
2.14.1
2.14.2
2.14.3
2.14.4
2.14.5 ß2-sympathomimetics 373
2.14.6
2.14.7
2.14.8
2.14.9
2.14.10
2.14.11
2.14.12
2.14.13
2.15
Elvira Rodriguez-Pinilla and
2.15.1
2.15.2
Contents xiii
2.15.3
Prolactin antagonists
386
2.15.4
Posterior pituitary hormones
387
2.15.5
Thyroid function and iodine supply during pregnancy
388
2.15.6
Hypothyroidism, triiodothyronine (T3), and thyroxine (T4)
389
2.15.7
Hyperthyroidism and thyrostatics
390
2.15.8
Glucocorticoids
392
2.15.9
Diabetes mellitus and pregnancy
397
2.15.10
Insulin
399
2.15.11
Oral antidiabetics
401
2.15.12
Estrogens
404
2.15.13
Progesti
405
2.15.14
Diethylstilbestrol
408
2.15.15
Androgens and anabolics
408
2.15.16
Antiestrogens, antiandrogens, and danazol
409
2.15.17
Mifepristone (RU486)
410
2.15.18
Clomiphene
411
2.16
I and local anesthetics and muscle
423
Asher
2.16.1
Halogenated inhalation agents for general anesthesia
424
2.16.2
Ether (diethyl ether)
426
2.16.3
Nitrous oxide
427
2.16.4
Injectable
427
2.16.5
Local anesthetics
431
2.16.6
Epidural and spinal analgesia/anesthesia in pregnancy
432
2.16.7
Muscle
433
2.16.8
Occupational exposure to inhalation anesthetics
434
2.17
441
Paul Peters and
2.17.1
Typical skin changes during pregnancy
441
2.17.2
Anti-infective agents
442
2.17.3
Antiseptics and disinfectants
444
2.17.4
Astringents
447
2.17.5
Polidocanol
448
2.17.6
Camphor and menthol
448
2.17.7
Coal tar and slate oil preparations
448
2.17.8
Local immunomoduiators and neurodermatitis therapy
449
2.17.9
Keratolytics
449
2.17.10
Retinoids for acne and psoriasis therapy
452
2.17.11
Photochemotherapy and
456
2.17.12
Sex hormones and cyproterone acetate
456
2.17.13
S-Fluorouracil
457
xiv Contents
2.17.14 Lithium 457
2.17.15
2.17.16 Diethyltoluamide
2.17.17
2.17.18
2.17.19
2.17.20
2.17.21
2.17.22
2.18
Paul Peters and
2.18.1
468
2.18.2
470
2.18.3
470
2.18.4
471
2.18.5
471
2.18.6
471
2.18.7
472
2.18.8
474
2.18.9
475
2.18.10
476
2.18.11
476
2.18.12
477
2.18.13
477
2.18.14
478
2.18.15
479
2.18.16
479
2.18.17
480
2.18.18
481
2.18.19
481
2.19
Henry M. Hess and Richard K. Miller
2.19.1
2.19.2
2.19.3
pregnancy
2.19.4
2.19.5
2.19.6
2.19.7
2.19.8
Contents xv
2.20
2.21
2.22
Diagnostic agents
502
Elisabeth Robert-Gnansia
2.20.1
502
2.20.2
505
2.20.3
506
2.20.4
507
2.20.5
507
2.20.6 Ultrasonographic
508
2.20.7
508
2.20.8
509
2.20.9
510
2.20.10
510
Recreational drugs
514
Paul Peters and
2.21.1
514
2.21.2
520
2.21.3
521
2.21.4
525
2.21.5
525
2.21.6
527
2.21.7
530
2.21.8
533
Poisonings and toxins
543
Christof
2.22.1
543
2.22.2
544
2.22.3
545
2.22.4
549
2.22.5
554
2.22.6
555
2.22.7
556
2.22.8
556
2.23
Richard K. Miller, Paul Peters, and Patricia R. McElhatton
2.23.1
2.23.2
2.23.3
2.23.4
2.23.5
xvi Contents
2.23.6
576
2.23.7
dibenzo-dioxins
581
2.23.8
583
2.23.9
590
2.23.10
592
2.23.11
594
2.23.12
596
2.23.13
596
2.23.14
598
General commentary on drug therapy and drug risk
during lactation
Ruth Lawrence and
3.1
medication
3.2
3.3
3.4
3.5
3.6
3.7
3.8
Christof
4.1
Christof
4.1.1
4.1.2
4.1.3
4.1.4
4.1.5
4.1.6
4.1.7
4.1.8
4.1.9
4.1.10
4.1.11
4.1.12
Contents xvii
4.2
4.3
4.4
Antiallergics, antiasthmatics and antitussives
639
Christof Schaefer
4.2.1
Antihistamines
639
4.2.2
ß2-sympathomimetics
641
4.2.3
Other sympathomimetics
642
4.2.4
Anticholinergics for asthma treatment
642
4.2.5
Theophylline
642
4.2.6
Cromoglycic acid and nedocromil
643
4.2.7
Corticoids
643
4.2.8
Leukotrien-receptor antagonists
644
4.2.9
Acetylcysteine and other mucolytics
644
4.2.10
Antitussives
644
Gastrointestinal drugs
648
Christof Schaefer
4.3.1
Antacids
648
4.3.2
H2-receptor
649
4.3.3
Peristaltic stimulators
650
4.3.4
Cholinergics
651
4.3.5
Anticholinergic spasmolytics
652
4.3.6
Laxatives
652
4.3.7
Agents used for chronic inflammatory bowel diseases
653
4.3.8
Antidiarrheals for acute diarrhea
654
4.3.9
Carminatives
654
4.3.10
Lipid
655
4.3.11
Chenodeoxycholic acid and ursodeoxycholic acid
655
4.3.12
Appetite suppressants
656
4.3.13
Antiemetics
656
Anti-infectives
659
Christof Schaefer
4.4.1
Antibiotics in general
660
4.4.2
Penicillins, cephalosporins, and other
660
4.4.3
Erythromycin and other macrolides
661
4.4.4
Tetracyclines
662
4.4.5
Dapsone, nitrofurantoin, and other drugs for urinary
tract infections
662
4.4.6
Quinolones
663
4.4.7
Other antibiotics and urinary tract antiseptics
664
4.4.8
Nitroimidazole antibiotics
665
4.4.9
Aminoglycoside antibiotics
665
4.4.10
Tuberculostatics
666
4.4.11
Malarial drugs
667
4.4.12
Local antimvcotics
668
xviii Contents
4.4.13
4.4.14
4.4.15
4.5
Ruth Lawrence and Christof Schaefer
4.5.1
4.5.2
4.5.3
4.5.4
4.5.5
4.5.6
4.5.7
4.5.8
4.5.9
4.5.10
4.5.11
680
682
682
683
684
684
685
686
686
687
690
4.6.12
4.7
Christof
695
696
696
697
699
700
700
4.6
Christof
4.6.1
ß-reeeptor blockers
4.6.2
Hydralazine
4.6.3
α
4.6.4
Calcium antagonists
4.6.5
ACE inhibitors
4.6.6
Angiotensin-ll receptor-antagonists
4.6.7
Other antihypertensives
4.6.8
Dihydroergotamine and other antihypotensives
4.6.9
Digitalis
4.6.10
Antiarrhythmics
4.6.11
Diuretics
4.7.1
Hepann
4.7.2
Vitamin
indanediones)
4.7.3
Other anticoagulants
4.7.4
Fibrinolytics
4.8
Christof
4.8.1
Carbamazepine
4.8.2
Clobazam and clonazepam
Contents xix
4.8.3
4.8.4
barbexaclone
4.8.5
4.8.6
4.8.7
4.8.8
4.8.9
4.8.10
4.8.11
4.8.12
4.8.13
4.8.14
4.8.15
4.9
708
709
714
718
720
724
724
727
727
730
731
732
732
4.10
Ruth Lawrence and
4.10.1
4.10.2
4.11
Christof
4.11.1
4.11.2
4.11.3
4.11.4
4.11.5
4.11.6
Psychotropic drugs
Christof
4.9.1
Antidepressants in general
4.9.2
Tri-
4.9.3
Selective serotonin reuptake inhibitors
4.9.4
Other antidepressants
4.9.5
Phenothiazine and thioxanthene neuroleptics
4.9.6
Butyrophenones
4.9.7
Atypical neuroleptics
4.9.8
Antimanic drugs
4.9.9
Benzodiazepines
4.9.10
Other anxiolytics
4.9.11
Other hypnotics
4.9.12
Psychoanaleptics
4.9.13
Parkinson drugs
XX
Contents
4.11.7 Corticosteroids
4.11.8
4.11.9 Insulin and oral antidiabetics
4.11.10 Estrogens,
4.11.11 Androgens
4.11.12
4.11.13 Prostaglandins
4.12 Dermatological
Ruth Lawrence and
4.12.1
products, sunscreens
4.12.2
4.12.3
4.12.4
4.12.5
4.12.6
4.12.7
4.13
Ruth Lawrence and
4.13.1
4.13.2
4.13.3
4.13.4
4.13.5
4.13.6
4.13.7
4.14
Ruth Lawrence and
4.14.1
4.14.2
4.14.3
4.14.4
4.14.5
4.14.6
4.15
Ruth Lawrence and
4.15.1
4.15.2
Simple infections
Mastitis
752
753
754
755
757
757
758
762
762
763
765
766
766
767
768
771
771
773
775
775
776
777
777
779
779
780
781
782
783
784
786
786
787
Contents xxi
787
788
788
790
790
791
791
793
794
794
797
797
798
800
800
801
803
804
4.17 Plant
Ruth Lawrence and Christof Schaefer
4.18
Christof Schaefer
4.18.1 Persistent organochlorine
polychlorinated biphenyls and dioxins) 811
4.18.2
4.18.3
4.18.4
4.18.5
4.18.6
4.18.7
Appendix A: Teratology information services and centers
Appendix B: Addresses for breastfeeding support
Subject index
4.15.3
Hepatitis A
4.15.4
Hepatitis
4.15.5
Hepatitis
4,15.6
Hepatitis
4.15.7
Herpes simplex
4.15.8
Herpes zoster (shingles), chickenpox
4.15.9
HIV
4.15.10
Human cytomegalovirus
4.15.11
Tuberculosis
4.15.12
Other infectious diseases
4.16
Ruth Lawrence and
4.16.1
Alcohol
4.16.2
Caffeine
4.16.3
Cannabis
4.16.4
Cocaine
4.16.5
Nicotine
4.16.6
Opiates, including methadone
4.16.7
Other drugs |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author_GND | (DE-588)132428474 |
| building | Verbundindex |
| bvnumber | BV022399517 |
| callnumber-first | R - Medicine |
| callnumber-label | RG627 |
| callnumber-raw | RG627.6.D79 |
| callnumber-search | RG627.6.D79 |
| callnumber-sort | RG 3627.6 D79 |
| callnumber-subject | RG - Gynecology and Obstetrics |
| classification_rvk | XI 2368 |
| ctrlnum | (OCoLC)170029613 (DE-599)BVBBV022399517 |
| dewey-full | 618.32 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 618 - Gynecology, obstetrics, pediatrics, geriatrics |
| dewey-raw | 618.32 |
| dewey-search | 618.32 |
| dewey-sort | 3618.32 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| edition | 2. ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02760nam a2200685zc 4500</leader><controlfield tag="001">BV022399517</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20070711 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">070424s2007 ne |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780444520722</subfield><subfield code="9">978-0-444-52072-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0444520724</subfield><subfield code="9">0-444-52072-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)170029613</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV022399517</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">ne</subfield><subfield code="c">NL</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-Er8</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RG627.6.D79</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">618.32</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 2368</subfield><subfield code="0">(DE-625)152984:12975</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drugs during pregnancy and lactation</subfield><subfield code="b">treatment options and risk assessment</subfield><subfield code="c">ed. by Christof Schaefer ...</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Amsterdam [u.a.]</subfield><subfield code="b">Elsevier, Acad. Press</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXV, 875 S.</subfield><subfield code="e">Beil.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Therapy</subfield><subfield code="x">adverse effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fetus</subfield><subfield code="x">Effect of drugs on</subfield><subfield code="v">Handbooks, manuals, etc</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fetus</subfield><subfield code="x">drug effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Infant, Newborn</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lactation</subfield><subfield code="x">drug effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Newborn infants</subfield><subfield code="x">Effect of drugs on</subfield><subfield code="v">Handbooks, manuals, etc</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Obstetrical pharmacology</subfield><subfield code="v">Handbooks, manuals, etc</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pregnancy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pregnancy</subfield><subfield code="x">drug effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pregnant women</subfield><subfield code="x">Drug use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pregnant women</subfield><subfield code="x">Medical care</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Stillperiode</subfield><subfield code="0">(DE-588)4183337-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Schwangerschaft</subfield><subfield code="0">(DE-588)4053724-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Stillen</subfield><subfield code="0">(DE-588)4057578-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelnebenwirkung</subfield><subfield code="0">(DE-588)4003134-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Stillperiode</subfield><subfield code="0">(DE-588)4183337-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Schwangerschaft</subfield><subfield code="0">(DE-588)4053724-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Schwangerschaft</subfield><subfield code="0">(DE-588)4053724-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Stillen</subfield><subfield code="0">(DE-588)4057578-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="2"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="3"><subfield code="a">Arzneimittelnebenwirkung</subfield><subfield code="0">(DE-588)4003134-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schaefer, Christof</subfield><subfield code="d">1951-</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)132428474</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015608213&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-015608213</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield></record></collection> |
| id | DE-604.BV022399517 |
| illustrated | Not Illustrated |
| index_date | 2024-07-02T17:17:50Z |
| indexdate | 2024-07-09T20:56:45Z |
| institution | BVB |
| isbn | 9780444520722 0444520724 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-015608213 |
| oclc_num | 170029613 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-Er8 DE-19 DE-BY-UBM |
| owner_facet | DE-355 DE-BY-UBR DE-Er8 DE-19 DE-BY-UBM |
| physical | XXV, 875 S. Beil. |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | Elsevier, Acad. Press |
| record_format | marc |
| spelling | Drugs during pregnancy and lactation treatment options and risk assessment ed. by Christof Schaefer ... 2. ed. Amsterdam [u.a.] Elsevier, Acad. Press 2007 XXV, 875 S. Beil. txt rdacontent n rdamedia nc rdacarrier Drug Therapy adverse effects Fetus Effect of drugs on Handbooks, manuals, etc Fetus drug effects Infant, Newborn Lactation drug effects Newborn infants Effect of drugs on Handbooks, manuals, etc Obstetrical pharmacology Handbooks, manuals, etc Pregnancy Pregnancy drug effects Pregnant women Drug use Pregnant women Medical care Stillperiode (DE-588)4183337-5 gnd rswk-swf Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Arzneimittel (DE-588)4003115-9 gnd rswk-swf Schwangerschaft (DE-588)4053724-9 gnd rswk-swf Stillen (DE-588)4057578-0 gnd rswk-swf Arzneimittelnebenwirkung (DE-588)4003134-2 gnd rswk-swf Stillperiode (DE-588)4183337-5 s Arzneimittel (DE-588)4003115-9 s DE-604 Schwangerschaft (DE-588)4053724-9 s Stillen (DE-588)4057578-0 s Pharmakotherapie (DE-588)4076066-2 s Arzneimittelnebenwirkung (DE-588)4003134-2 s 1\p DE-604 Schaefer, Christof 1951- Sonstige (DE-588)132428474 oth Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015608213&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Drugs during pregnancy and lactation treatment options and risk assessment Drug Therapy adverse effects Fetus Effect of drugs on Handbooks, manuals, etc Fetus drug effects Infant, Newborn Lactation drug effects Newborn infants Effect of drugs on Handbooks, manuals, etc Obstetrical pharmacology Handbooks, manuals, etc Pregnancy Pregnancy drug effects Pregnant women Drug use Pregnant women Medical care Stillperiode (DE-588)4183337-5 gnd Pharmakotherapie (DE-588)4076066-2 gnd Arzneimittel (DE-588)4003115-9 gnd Schwangerschaft (DE-588)4053724-9 gnd Stillen (DE-588)4057578-0 gnd Arzneimittelnebenwirkung (DE-588)4003134-2 gnd |
| subject_GND | (DE-588)4183337-5 (DE-588)4076066-2 (DE-588)4003115-9 (DE-588)4053724-9 (DE-588)4057578-0 (DE-588)4003134-2 |
| title | Drugs during pregnancy and lactation treatment options and risk assessment |
| title_auth | Drugs during pregnancy and lactation treatment options and risk assessment |
| title_exact_search | Drugs during pregnancy and lactation treatment options and risk assessment |
| title_exact_search_txtP | Drugs during pregnancy and lactation treatment options and risk assessment |
| title_full | Drugs during pregnancy and lactation treatment options and risk assessment ed. by Christof Schaefer ... |
| title_fullStr | Drugs during pregnancy and lactation treatment options and risk assessment ed. by Christof Schaefer ... |
| title_full_unstemmed | Drugs during pregnancy and lactation treatment options and risk assessment ed. by Christof Schaefer ... |
| title_short | Drugs during pregnancy and lactation |
| title_sort | drugs during pregnancy and lactation treatment options and risk assessment |
| title_sub | treatment options and risk assessment |
| topic | Drug Therapy adverse effects Fetus Effect of drugs on Handbooks, manuals, etc Fetus drug effects Infant, Newborn Lactation drug effects Newborn infants Effect of drugs on Handbooks, manuals, etc Obstetrical pharmacology Handbooks, manuals, etc Pregnancy Pregnancy drug effects Pregnant women Drug use Pregnant women Medical care Stillperiode (DE-588)4183337-5 gnd Pharmakotherapie (DE-588)4076066-2 gnd Arzneimittel (DE-588)4003115-9 gnd Schwangerschaft (DE-588)4053724-9 gnd Stillen (DE-588)4057578-0 gnd Arzneimittelnebenwirkung (DE-588)4003134-2 gnd |
| topic_facet | Drug Therapy adverse effects Fetus Effect of drugs on Handbooks, manuals, etc Fetus drug effects Infant, Newborn Lactation drug effects Newborn infants Effect of drugs on Handbooks, manuals, etc Obstetrical pharmacology Handbooks, manuals, etc Pregnancy Pregnancy drug effects Pregnant women Drug use Pregnant women Medical care Stillperiode Pharmakotherapie Arzneimittel Schwangerschaft Stillen Arzneimittelnebenwirkung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015608213&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT schaeferchristof drugsduringpregnancyandlactationtreatmentoptionsandriskassessment |